Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


June 18-20, 2019
Park Central Hotel,
San Francisco, CA

Looking beyond antibodies to transform promising next generation proteins into next generation medicine

Employ the creativity behind protein engineering and design into innovative biologics. Maximize the therapeutic window with fresh perspectives and cutting-edge targets.

Accelerate promising new molecules into differentiated products

Next Generation Bioconjugates
  • Learn about novel conjugation techniques and technology to create a more cost effective, high efficacy, easier process.
  • Tackle bioconjugations beyond antibodies and cytotoxins: What are the next generation delivery vehicles and modalities?
  • Overcome bioconjugate challenges by maximizing your therapeutic window and maintaining stability. 
Creative Engineering & Design
  • See the latest expansion of antibody mimetic molecules and the future of these promising therapeutic proteins in a clinical setting.
  • Uncover creative engineering and design approaches for next generation protein therapeutics: Bi and multi specifics, Bispecific T cell engagers, Non-Antibody Scaffolds, Checkpoint Inhibitors and Peptoids.  
  • Are you up-to-date on the use of novel protein therapeutics for diseases outside of oncology?
Drug Design, Delivery & Patient Welfare
  • Discover how the use of systems and synthetic biology can be used to identify novel targets.
  • Delve into Bispecific design and production to achieve a product with maximum quality.
  • Achieve delivery into cells and across the blood-brain barrier.
  • What do doctors look for in new drugs and how can side effects be reduced?

The Leading Meeting for Bioconjugates and Next Generation Protein Therapeutics

Case Studies and New Data Presentations
Attendees from Pharmaceutical, Biotech, and Solution Providers
Experts and Scientists presenting new data and case studies

Present a Scientific Poster

Share your company's new research by presenting a poster at Cell Line Development & Engineering.  All posters are displayed in the Poster & Exhibit Hall throughout the event.

Please note that all poster presenters must be registered attendees.  The deadline to submit your abstract is May 27, 2019. 

Exclusive Whitepaper Downloads

Innovative Development Strategies and Applications for Bispecific Antibodies

The phenomenal growth of the bispecific antibody arena has culminated in 60 unique constructs, more than 30 in clinical development, and two on the market as therapeutics for a wide variety of cancer types and numerous diseases/disorders. Bispecific antibodies are specially engineered antibodies which simultaneously bind to two different epitopes on the same antigen or different antigens, increasing selectivity and effectiveness.

Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies

The last decade has seen substantial growth of immunotherapy treatments for cancer. The new immunotherapies have produced exciting results in terms of response rates to treatment for certain cancers, such as melanoma, which have been refractory to treatment, once substantial metastasis has occurred. The US Food and Drug Administration (FDA) has approved several antibodies against immune checkpoint inhibitors based on the encouraging results in clinical trials. Other types of immune therapies are also being developed which may also be useful in the treatment of cancer.

Sponsorship & Exhibition Opportunities

Showcase the adaptability of your products to leading scientists representing the upstream development and bioprocessing chain, spanning early stage discovery to early stage development.

For more information or to begin building your custom sponsorship package today, contact Kristin Skahan at  (857) 504-6730 or